Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of genoss® des in patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the objective of this study is to evaluate the efficacy and safety of the genoss des in patients with coronary artery disease in real-world pratice.

the genoss des is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. although the efficacy and safety of this stent have been previously investigated, real-world clinical outcomes data are lacking. therefore, the objective of this prospective, multicenter study was to evaluate the clinical efficacy and safety of the genoss des in all-comer patients undergoing percutaneous coronary intervention. the genoss des registry is a prospective, single-arm, observational study for evaluation of clinical outcomes after genoss des implantation in all-comer patients undergoing percutaneous coronary intervention from 12 sites in south korea. the primary endpoint was a device-oriented composite endpoint (doce), defined as a composite of cardiac death, target vessel-related myocardial infarction (mi), and clinically indicated target lesion revascularization (tlr) at 12 months.

Eligibility criteria:
\ 1. patients of 19 and over 2. patients eligible for treatment of coronary artery disease using genosstm des 3. participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as research participants. \ 1. patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents (however, patients with hypersensitivity to contrast agents may be eligible if it can be controlled by steroids and pheniramine. patients with known anaphylaxis are excluded) 2. patients who are pregnant or planning to become pregnant 3. patients scheduled to undergo surgery requiring the discontinuation of antiplatelet agents within 12 months from registration 4. patients with a life expectancy of less than 1 year 5. patients who presented with cardiogenic shock at admission and are predicted to have a low chance of survival based on medical judgment 6. patients who have already received treatment with another des (drug eluting stent), bvs (bioresorbable vascular scaffolds), or bms (bare metal stent) at the time of registration 7. patients currently participating in a randomized controlled trial involving medical devices
3 limus agent eluting stents with different polymer coating

Conditions: Coronary Heart Disease

Summary: the aim of this study is to determine whether biodegradable polymer based rapamycin-eluting stent performs equal to permanent polymer based everolimus- and rapamycin-eluting stents regarding reduction of adverse cardiac events at one year.

drug-eluting stents significantly reduce in-stent restenosis and the subsequent need for target vessel revascularisation compared with bare metal stents. although this applies to the vast majority of patients, intimal hyperplasia and in-stent restenosis have not been completely eliminated and remain to occur in certain high risk subgroups. thus there is ongoing research for new, potentially more effective and safe drug-eluting stent systems. one direction of extensive research is the search of new polymers such as biodegradable polymers which allow a controlled drug-release and disappear with time, reducing the probability of polymer-induced chronic inflammation on the vessel wall. another direction is finding new drugs to suppress neointimal hyperplasia. promising preclinical and clinical results suggest that the everolimus eluting stent platform might provide potential improvements over prior generations of drug-eluting stents.

Eligibility criteria:
inclusion criteria: * patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels. * written, informed consent by the patient or her/his legally-authorized representative for participation in the study. * in women with childbearing potential a negative pregnancy test is mandatory exclusion criteria: * target lesion located in the left main trunk. * target lesion located in the bypass graft. * in-stent restenosis. * cardiogenic shock. * malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. * known allergy to the study medications: clopidogrel, rapamycin, everolimus, stainless steel or cobalt chrome. * inability to take clopidogrel for at least 6 months. * pregnancy (present, suspected or planned) or positive pregnancy test. * previous enrollment in this trial. * patient's inability to fully cooperate with the study protocol
glp-1 agonism for blocking cocaine euphoria and self-administration

Conditions: Cocaine Dependence

Summary: the investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (glp-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. additionally, the investigators plan to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug.


Eligibility criteria:
inclusion criteria: 1. age 18 - 50 years, 2. voluntary, written, informed consent, 3. physically healthy by medical history, physical, neurological, ecg, and laboratory examinations, 4. dsm-iv criteria for cocaine abuse (305.60) or cocaine dependence (304.20) 5. recent street cocaine use in excess of amounts to be administered in the current study, 6. intravenous and/or smoked (crack/ freebase) use, 7. positive urine toxicology screen for cocaine, 8. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (β-hcg) test. exclusion criteria: 1. other drug dependence (except nicotine) as determined by urine toxicology or interview 2. \< 1 year of cocaine dependence, 3. a primary major dsm-iv psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine, 4. a history of significant medical (cardiovascular) or neurological illness, ie prior myocardial infarction, current active symptoms of cardiovascular disease / angina, evidence of cocaine-related cardiovascular symptoms, prior arrhythmias or need for cardiovascular resuscitation, neurovascular events such as transient ischemic attacks, stroke, and/or seizures parameters re: elevations in vital signs are now explicitly specified under "safety features built into our one-day self-administration paradigm). 5. current use of psychotropic and/or potentially psychoactive prescription medication, 6. seeking treatment for drug abuse/dependence (for experimental cocaine component), 7. physical or laboratory (β-hcg) evidence of pregnancy. 8. current use of any medication (prescription or over-the-counter) determined to cause potential drug interactions by the study physicians.
a pilot open label trial of hiv therapy with d4t (stavudine), ddi (didanosine), nelfinavir and hydroxyurea in subjects with early asymptomatic hiv infection

Conditions: HIV Infections

Summary: to assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable hiv rna in plasma. to assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of this therapy over cd4 cell counts.


Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * cd4 count \> 500 cells/mm3. * no hiv-associated symptoms. * written, informed consent from parent or legal guardian for patients \< 18 years old. * availability for follow-up for at least 96 weeks. exclusion criteria co-existing condition: patients with the following conditions and symptoms are excluded: * presence of a newly diagnosed aids-defining opportunistic infection requiring acute therapy at the time of enrollment. * intractable diarrhea. * signs and symptoms of bilateral peripheral neuropathy \>= grade 2. * inability to tolerate oral medication. * hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue. patients with the following prior conditions are excluded: history of acute or chronic pancreatitis. 1. use of potent neurotoxic drugs is not permitted. * no other anti-hiv therapy allowed. * nelfinavir should not be administered concurrently with rifampin or rifabutin, terfenadine (seldane), astemizole (hismanal), cisapride (propulsid), triazolam (halcion), and midazolam (versed). 1. any prior antiretroviral therapy. * prior vaccination with a candidate hiv therapeutic vaccine. * previous therapy with agents with significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment. * previous therapy with rifampin or rifabutin, terfenadine (seldane), astemizole (hismanal), cisapride (propulsid), triazolam (halcion), and midazolam (versed) within 14 days prior to study entry or at any time while on study. active alcohol or substance abuse.

Keywords: pilot projects didanosine drug therapy, combination stavudine hydroxyurea nelfinavir anti-hiv agents viral load
perioperative copeptin: predictive value and risk stratification in patients undergoing major surgery

Conditions: Perioperative Myocardial Injury

Summary: observational cohort study examining the perioperative course of copeptin in patients undergoing elevated-risk surgery.


Eligibility criteria:
inclusion criteria: * adults \>18 years * type of surgery for patients 1 to 30: abdominal aortic aneurysm repair, suprainguinal and infrainguinal vascular surgery, carotid surgery * type of surgery for patients 31 to 500: surgeries with elevated risks in general (as specified by 2014 esc/esa guidelines on non-cardiac surgery: cardiovascular assessment and management \[kristensen\]) exclusion criteria: * acute coronary syndrome (acs) at presentation (clinical assessment or documentation) * congestive heart failure at presentation (clinical assessment or documentation) * documented severe aortic stenosis (valve area \<1cm2) * kidney dysfunction (clearance \<50ml/min) * reduced left ventricular ejection fraction (lvef) (\ 40% * cancelled surgery * unwilling or unable to provide consent * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant

Keywords: copeptin, human
premature birth and its sequelae in women

Conditions: Bronchopulmonary Dysplasia; Lung Diseases

Summary: to establish in children born prematurely a set of links between lung function in late infancy and lung function at school age, between lung function at school age and that in adolescence, and between lung function in adolescence and that in adulthood in order to evaluate pulmonary outcomes of neonatal therapeutic strategies and to relate these strategies to lung health in adult life.

background: effective perinatal treatment strategies during the past 20 years have increased the survival of low birth weight infants. accompanying this increased survival has been a 4-6 fold increase in the number of children surviving with bronchopulmonary dysplasia, although the birthweight specific incidence has remained constant or declined. limited data currently available indicate that individuals who had bpd as infants have, as childrearing adults, impaired lung growth as well as both fixed and reversible airways obstruction. the study was part of an institute-initiated program on collaborative projects in women's health. the concept was developed by the nhlbi staff and given concept clearance at the february 1992 national heart, lung, and blood advisory council. the request for applications was released in april 1992. design narrative: the study was part of a four-grant collaborative project on women's health. based on available data, dr. mary ellen wohl hypothesized that bronchopulmonary dysplasia (bpd) morbidity was related to impaired lung growth in the first year of life, did not improve during adolescence and was accentuated in females because of their intrinsically smaller lungs. to test this hypothesis, she measured lung size and airway function in teenagers and young adults, previously studied at school age, who were born, 1) at term, 2) prematurely, 3) developed respiratory distress syndrome of the newborn (rds) or 4) developed bpd. children born from 1987-89 previously studied at 10 months of age by novel lung function function methods developed in this laboratory were restudied at school age. techniques of measuring total respiratory system compliance and resistance and of obtaining forced expiratory flow at functional residual capacity were applied to cohorts of born premature infants at 10-18 months of age to assess outcome of current perinatal strategies. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
artificial intelligence in breast cancer screening programs in córdoba (aitic)

Conditions: Breast Cancer

Summary: the use of artificial intelligence software in breast screening (transpara®) makes it possible to identify studies with a very low probability of cancer. the hypothesis raised in this work is that reading strategies based on artificial intelligence (single or double reading only of cases with a score\> 7 with transpara®), allow reducing the workload of a screening program by more than 50 % with respect to the standard reading of the program (double reading of all cases without transpara®), without presenting inferiority in terms of detection rates and recalls of the program, both with the use of 2d digital mammography and with the use of tomosynthesis or 3d mammogram.


Eligibility criteria:
inclusion criteria: * any woman between the ages of 50 and 69, from the hospital area of the reina sofía university hospital, invited to the breast cancer early detection program, summoned in rooms 2024 and 2001 and who agrees to participate in the study by signing the consent informed. * women studied in the program in the set period and who have previously participated. * women who are studied in the program for the first time in the set period. exclusion criteria: * women invited to the program who do not agree to enter the research study by signing the informed consent. * women with breast prostheses. * women with symptoms or signs of suspected breast cancer.

Keywords: breast cancer artificial intelligence
population-based estimates of medical comorbidities in women with lower urinary tract symptoms or pelvic organ prolapse

Conditions: Lower Urinary Tract Symptoms; Pelvic Organ Prolapse

Summary: the purpose of this study is to investigate the comorbidities of lower urinary tract symptoms or pelvic organ prolapse in a nationwide population-based data in taiwan during the study period of 2001-2010, a total of 10 years.


Eligibility criteria:
inclusion criteria: * all cases with lower urinary tract symptoms

Keywords: women
enthesis differences in rheumatoid arthritis and axial spondyloarthropathy

Conditions: Axial Spondyloarthritis; Rheumatoid Arthritis; Enthesitis; Enthesopathy

Summary: the aim of this study is to investigate the sonographic differences in entheses in patients with rheumatoid arthritis and axial spondyloarthropathy.

after recording the demographic data of the patients; 5 enthesis regions 5 enthesis sites were evaluated bilaterally as ''tricipital tendon (tt), quadricipital tendon (qt), proximal patellar tendon (ppt), distal patellar tendon (dpt), achilles tendon (at)'' will be sonographically evaluated and the presence of hypoechogenicity , tendon thickness increase, power doppler activity, erosion, presence of entezophyte/calcification will be investigated. the differences between the groups will then be compared.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis patients identified according to the 2010 american college of rheumatology /europan leage against rheumatism classification criteria, * axial spondyloarthrtis patients identified according to the assessment of spondyloarthritis classification criteria * healthy controls with no history of rheumatic diseases. exclusion criteria: * history of limb trauma and surgery in the last 3 months, * metabolic disease (diabetes mellitus, hypothyroidism), * malignant neoplasm, * limitation of range of motion in the extremity, * those who have received corticosteroid injections in the last 3 months, * uncontrollable fibromyalgia.

Keywords: axial spondyloarthritis, rheumatoid arthritis enthesitis ultrasound
suspension syndrome

Conditions: Circulatory Collapse; Circulatory Failure; Syncope, Vasovagal, Neurally-Mediated; Orthostatic Hypotension

Summary: suspension syndrome refers to a potentially life-threatening condition that can occur in unconscious persons after prolonged suspension in a harness. to date, our understanding of the pathophysiology and appropriate treatment is based primarily on case reports and expert opinion. the main pathophysiological hypothesis implicates blood pooling in the lower extremity and lack of return via muscle pumping. however, a recent french study could not support this hypothesis. other mechanisms, such as a central vagal reflex may play a role in the pathophysiology of suspension syndrome. the aim of this study is to better understand the pathophysiological basis of suspension syndrome and to develop practical recommendations for prevention and treatment.


Eligibility criteria:
inclusion criteria: * healthy volunteers * age 18-50 years * asa class 1 * signed informed consent exclusion criteria: * age \ 50 years * asa class \>1 * informed consent not signed
evaluating quality of life for patients with chronic obstructive pulmonary disease who are undergoing lung transplantation

Conditions: Pulmonary Disease, Chronic Obstructive; Lung Transplantation

Summary: most people undergoing lung transplantation have chronic obstructive pulmonary disease (copd), a disease in which the lung airways are partly damaged and obstructed, making it difficult to breathe. this study will enroll people with copd who are undergoing a lung transplant to examine how their quality of life changes after the transplant procedure.

lung transplantation is one treatment option for people with end-stage lung disease. the majority of people undergoing a lung transplant have copd, and while transplantation can potentially improve survival and quality of life, it may also carry substantial risks, including surgical complications, infections, and pneumonia. the impact of lung transplantation on survival and quality of life has not been extensively studied. in the united states, the united network for organ sharing (unos) is the organization that allocates donor lungs to lung recipients. before 2005, the length of time that a candidate had been on the transplant waiting list was the major determining factor for receiving a donor lung. in mid 2005, the unos system changed and began prioritizing candidates on the basis of risk of death prior to lung transplantation and the probability of death within the first year after transplantation. the purpose of this study is to evaluate quality of life factors for lung transplant patients with copd, both before and after the lung transplant procedure. in addition, quality of life of patients in the new unos allocation system will be compared with that of patients in the old unos allocation system. this study will enroll all copd patients undergoing an evaluation for lung transplantation at the washington university medical center and barnes-jewish hospital in st. louis, missouri. participants will attend study visits at the time of the transplant evaluation and again just prior to listing in the unos system. after the transplant, participants will attend study visits at months 3 and 6 and then once a year for 5 years. during each study visit, participants will complete a computerized interview and health-related questionnaires that will assess quality of life factors, including social life, work life, and home life. study researchers will also review participants' medical records to collect information on lung function and blood test results.

Eligibility criteria:
inclusion criteria: * referred to the adult lung transplant program * undergoing evaluation for lung transplantation * very severe copd (global initiative for chronic obstructive lung disease \[gold\] class iv) that is predominantly due to emphysema * able to read english * able to adequately see a computer screen exclusion criteria: * diagnosis other than copd * inability to read english

Keywords: copd lung transplant quality of life end stage lung disease
characteristics of hoffa adipose tissue and intramuscular adipose tissue in the quadriceps muscle

Conditions: Osteo Arthritis Knee

Summary: over the last few years, it has been suggested that knee ostheoarthritis (koa) incidence and progression could potentially be related to skeletal muscle characteristics. in particular, weakness of the quadriceps muscle would be a key determinant of koa. however the mechanisms underpinning the influence of skeletal muscle in the pathophysiology of ostheoarthritis (oa) are poorly understood. crosstalk between skeletal muscle and structures around and in the joint is of interest. in physical deconditioning and aging, it has been reported that skeletal muscle can be replaced by adipose tissue. several factors involved in the development of oa but also of adipose tissue may be involved in these muscular changes. of interest, in patients with koa, quadriceps weakness is an ubiquitous clinical finding. infiltration of adipose tissue in skeletal muscle has been shown to affect muscle strength and mobility and be linked to cartilage volume loss and the occurrence/progression of koa. the main objective of this study is to compare the characteristics of the hoffa tissus and the intamuscular fat (imf) tissus in the quadriceps muscle in patients with gonarthrosis requiring total knee prosthesis. this is a single-centre study based on a collection of surgical waste and is categorized as research not involving human subjects.


Eligibility criteria:
inclusion criteria: * adult patient, aged between 40 and 85 years * patient having a confirmed diagnosis of knee ostheoarthritis * patient undergoing a surgery for a total knee prosthesis for knee ostheoarthritis exclusion criteria: -